CSPI on AER bill
This article was originally published in The Tan Sheet
Executive SummaryThe Center for Science in the Public Interest applauds the passage of the Dietary Supplement & Nonprescription Drug Consumer Protection Act Dec. 11 and says it hopes Congress "now provides sufficient funding so that the FDA can quickly respond to reports of adverse reactions and promptly remove hazardous products from the marketplace". Both consumer groups and major industry trade groups campaigned for the bill. "It's refreshing, and it's a pleasure, to see that those who are historically critical of the industry have been, I think, pleasantly surprised that the industry worked very hard to try and help move the bill," United Natural Products Alliance Executive Director Loren Israelsen said. "I hope that this kind of re-restores a bridge and a dialogue so that we can move on now to other issues," he added...
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.